Scope of the Report

The report titled “Global Injectable Drug Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global injectable market with detailed analysis of the actual and the expected market size along with the market size of each market segment.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global injectable drug market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The competition in the global injectable drug market is stiff and dominated by the big players like Pfizer, Inc. Further, key players of the injectable drug market such as Merck & Co., Inc., Novartis AG and Johnson & Johnson are also profiled with their financial information and respective business strategies.

Regional Coverage

- Global

Company Coverage

- Pfizer, Inc.
- Merck & Co., Inc.
- Novartis AG
- Johnson & Johnson

  Executive Summary

Injectable drugs are the drugs which are introduced into the body with a hollow needle and a syringe which is pierced through the skin into the body. Injections are among the most common health care procedures, with at least 16 billion administered in developing and transitional countries each year.

The global injectable drug market has increased at a significant CAGR during 2012-2015 and projections are made that the market would rise tremendously in the next five years i.e. 2016-2020. The growth in the market is driven by patient awareness, increase in per capita drug spending, a rise in the personal disposable income of individuals and etc. The market can be segmented into vaccines, insulin, conventional therapeutics and complex biologics. Of all the segments, complex biologics remains the largest segment of the market with the highest growth rate.

The major growth drivers for the injectable drug market are: rise in cancer incidences & diabetic population, the introduction of new products and increase in biologics & new drugs license approvals. Despite the market is governed by various growth drivers, there are certain challenges faced by the market such as high risk of re-operation or death, injectable drug safety issues and less patient compliance.